Phototherapy and topical treatments for cutaneous graft vs. host disease in haematopoietic stem cell transplantation patients: a scoping review.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
07
06
2021
accepted:
17
02
2022
pubmed:
14
3
2022
medline:
22
6
2022
entrez:
13
3
2022
Statut:
ppublish
Résumé
Skin is usually the first and most affected organ involved in graft-versus-host disease (GvHD), and treatment is still a clinical challenge. Although the need for skin-directed treatments such as physical treatments and topical medications are generally agreed on, what the gold standard treatment strategy should be remains open to debate. The aim of this scoping review was to synthesize the current knowledge on the topical and physical treatments of cutaneous GvHD in haematopoietic stem cell transplantation patients and to highlight the best evidence available so as to reduce the gap between 'what is known' and 'what is done' in the clinical practice. Twenty-eight studies were included in this qualitative synthesis. Photo-biomodulation with psoralen was not included in this review. Phototherapy (ultraviolet A or B or narrowband B) was the physical treatment most described in the literature in both acute GvHD and chronic GvHD. Topical calcineurin inhibitors such as tacrolimus ointment and pimecrolimus cream as well as corticosteroid creams such as clobetasol and triamcinolone are mainly used in case of chronic GvHD. In all of the studies included in the review, topical treatments were always associated with systemic therapy. None of the topical interventions identified in our review provided strong evidence supporting its use, and the topical approaches seemed to have an adjuvant role in the treatment of cutaneous GvHD.
Substances chimiques
Calcineurin Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1003-1015Informations de copyright
© 2022 European Academy of Dermatology and Venereology.
Références
Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet 2009; 373: 1550-1561.
Zeiser R, Blazar BR. Acute graft-versus-host disease - biologic process, prevention, and therapy. N Engl J Med 2017; 377: 2167-2179.
Carreras E, Dufour C, Mohty M, Kröger N, eds. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies [Internet], 7th edn. Springer, Charm (CH), 2019.
Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 2012; 12: 443-458.
Schoemans HM, Lee SJ, Ferrara JL et al. EBMT-NIH-CIBMTR task force position statement on standardized terminology & guidance for graft-versus-host disease assessment. Bone Marrow Transplant 2018; 53: 1401-1415.
Harris AC, Young R, Devine S et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the mount sinai acute GVHD international consortium. Biol Blood Marrow Transplant 2016; 22: 4-10.
Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from hla-matched sibling donors. Transplantation 1974; 18: 295-304.
Cho A, Paulitschke V, Just U, Knobler R. Cutaneous manifestations of acute and chronic graft-versus-host disease. G Ital di Dermatologia e Venereol 2020; 155: 76-87.
Friedman HZ, Arias AM, Catchatourian R, Fretzin DF. Toxic epidermal necrolysis following bone marrow transplantation. Cutis 1984; 34: 158-162.
Macedo FIB, Faris J, Lum LG et al. Extensive toxic epidermal necrolysis versus acute graft versus host disease after allogenic hematopoietic stem-cell transplantation: challenges in diagnosis and management. J Burn Care Res 2014; 35: e431-e435.
Vaidya TS, Menzer C, Ponce DM, Markova A. Inpatient management of mucocutaneous GVHD. Curr Dermatol Rep 2019; 8: 258-278.
Hogenes MCH, Te Boome LCJ, Van Der Valk DC et al. Clinical versus histological grading in the assessment of cutaneous graft versus host disease. Eur J Med Res 2019; 24: 19.
Jagasia MH, Greinix HT, Arora M et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015; 21: 389-401.e1.
Zeiser R, von Bubnoff N, Butler J et al. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med 2020; 382: 1800-1810.
Teusink-Cross A, Davies SM, Grimley MS et al. Ibrutinib for the treatment of chronic graft-vs-host disease in pediatric hematopoietic stem cell transplant patients: a single-center experience. Pediatr Transplant 2020; 24: e13692.
Penack O, Marchetti M, Ruutu T et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European society for blood and marrow transplantation. Lancet Haematol 2020; 7: e157-e167.
Campbell J, Gavin N, Button E, Roberts N. Skin and wound care for individuals with graft versus host disease: a scoping review protocol. BMJ Open 2020; 10: e38567.
Brice L, Gilroy N, Dyer G et al. Predictors of quality of life in allogeneic hematopoietic stem cell transplantation survivors. J Psychosoc Oncol 2021; 39: 534-552. https://doi.org/10.1080/07347332.2020.1870644
Kim YJ, Lee GH, Kwong BY, Martires KJ. Evidence-based, skin-directed treatments for cutaneous chronic graft-versus-host disease. Cureus 2019; 11: e6462.
Dignan FL, Clark A, Amrolia P et al. Diagnosis and management of acute graft-versus-host disease. Br J Haematol 2012; 158: 30-45.
Chavan R, El-Azhary R. Cutaneous graft-versus-host disease: rationales and treatment options. Dermatol Ther 2011; 24: 219-28.
Strong Rodrigues K, Oliveira-Ribeiro C, de Abreu Fiuza Gomes S, Knobler R. Cutaneous graft-versus-host disease: diagnosis and treatment. Am J Clin Dermatol 2018; 19: 33-50.
Arksey H, O’Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol Theory Pract 2005; 8: 19-32.
Tricco AC, Lillie E, Zarin W et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med 2018; 169: 467-473.
Greinix HT, Socié G, Bacigalupo A et al. Assessing the potential role of photopheresis in hematopoietic stem cell transplant. Bone Marrow Transplant 2006; 38: 265-273.
Marks C, Stadler M, Häusermann P et al. German-Austrian-Swiss consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): guidance for supportive therapy of chronic cutaneous and musculoskeletal GVHD. Br J Dermatol 2011; 165: 18-29.
van Dooren-Greebe RJ, Schattenberg A, Koopman RJJ. Chronic cutaneous graft-versus-host disease: successful treatment with UVB. Br J Dermatol 1991; 125: 498-9.
Enk CD, Elad S, Vexler A, Kapelushnik J, Gorodetsky R, Kirschbaum M. Chronic graft-versus-host disease treated with UVB phototherapy. Bone Marrow Transplant 1998; 22: 1179-1183.
Brazzelli V, Grasso V, Muzio F et al. Narrowband ultraviolet B phototherapy in the treatment of cutaneous graft-versus-host disease in oncohaematological paediatric patients. Br J Dermatol 2010; 162: 404-409.
Chen T, Khan SP, Rodriguez V, Tollefson M. Use of NB-UVB phototherapy in pediatric graft-versus-host disease patients. Biol Blood Marrow Transplant 2016; 22: S391.
Grundmann-Kollmann M, Martin H, Ludwig R et al. Narrowband UV-B phototherapy in the treatment of cutaneous graft versus host disease. Transplantation 2002; 74: 1631-1634.
Iyama S, Murase K, Sato T et al. Narrowband ultraviolet B phototherapy ameliorates acute graft-versus-host disease by a mechanism involving in vivo expansion of CD4+CD25+Foxp3+ regulatory T cells. Int J Hematol 2014; 99: 471-476.
Feldstein JV, Bolaños-Meade J, Anders VL, Abuav R. Narrowband ultraviolet B phototherapy for the treatment of steroid-refractory and steroid-dependent acute graft-versus-host disease of the skin. J Am Acad Dermatol 2011; 65: 733-8.
George L, Peter D, Chopra M et al. Efficacy of narrow band UVB in the treatment of cutaneous GvHD: an Indian experience. Bone Marrow Transplant 2016; 51: 988-990.
Snyder AN, Lee LW, Jaroscak JJ, Donahoo LB, Hudspeth M. Outcomes using narrow band uvb phototherapy for acute skin graft versus host disease (GVHD) in pediatric allogeneic hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2019; 25: S250.
Schlaak M, Schwind S, Wetzig T et al. UVA (UVA-1) therapy for the treatment of acute GVHD of the skin. Bone Marrow Transplant 2010; 45: 1741-1748.
Wetzig T, Sticherling M, Simon JC, Hegenbart U, Niederwieser D, Al-Ali HK. Medium dose long-wavelength ultraviolet A (UVA1) phototherapy for the treatment of acute and chronic graft-versus-host disease of the skin. Bone Marrow Transplant 2005; 35: 515-519.
Choi CJ, Nghiem P. Tacrolimus ointment in the treatment of chronic cutaneous graft-vs-host disease. Arch Dermatol 2001; 137: 1202-1206.
Gálvez Ramírez K, Muñoz P, Vera V, Arce C. Vitiligo type cutaneous manifestation of chronic graft-versus-host disease. Case report. Rev Chil Pediatr 2018; 89: 113-117.
Elad S, Or R, Resnick I, Shapira MY. Topical tacrolimus - A novel treatment alternative for cutaneous chronic graft-versus-host disease. Transpl Int 2003; 16: 665-670.
Wei J, Zhang Y, Xu H, Jin J, Zhang J. Atopic dermatitis-like presentation of graft-versus-host disease: a novel form of chronic cutaneous graft-versus-host disease. J Am Acad Dermatol 2013; 69: 34-39.
Olson KA, West K, McCarthy PL. Toxic tacrolimus levels after application of topical tacrolimus and use of occlusive dressings in two bone marrow transplant recipients with cutaneous graft-versus-host disease. Pharmacotherapy 2014; 34: e60-e64.
Ziemer M, Gruhn B, Thiele JJ, Elsner P. Treatment of extensive chronic cutaneous graft-versus-host disease in an infant with topical pimecrolimus. J Am Acad Dermatol 2004; 50: 946-948.
Schmook T, Kraft J, Benninghoff B et al. Treatment of cutaneous chronic graft-versus-host disease with topical pimecrolimus. Bone Marrow Transplant 2005; 36: 87-88.
Creamer D, Martyn-Simmons CL, Osborne G et al. Eczematoid graft-vs-host disease: a novel form of chronic cutaneous graft-vs-host disease and its response to psoralen-UV-A therapy. Arch Dermatol 2007; 143: 1157-1162.
Sharp H, Grosshans D, Kadia T, Dabaja BS. Cutaneous graft-versus-host disease after proton-based craniospinal irradiation for recurrent Philadelphia-positive acute lymphoblastic leukaemia. BMJ Case Rep 2012; 2012: bcr0220125742.
Shreberk-Hassidim R, Neumark M, Greenberger S et al. Cutaneous chronic graft versus host disease following allogeneic haematopoietic stem cell transplantation in children: a retrospective study. Acta Derm Venereol 2018; 98: 206-211.
Bashline B, Mortazie M, Schapiro B, Fivenson D. Graft-versus-host disease-associated angiomatosis treated with topical timolol solution. Wounds 2016; 28: e18-e21.
Currie DM, Ludvigsdottir GK, Diaz CA, Kamani N. Topical treatment of sclerodermoid chronic graft vs. host disease. Am J Phys Med Rehabil 2002; 81: 143-149.
Gryn J, Crilley P. Tretinoin for the treatment of cutaneous graft-versus-host disease. Bone Marrow Transpl 1990; 5: 279-280.
Labadie JG, Kosche C, Kyllo R et al. Fractional CO2 laser for the treatment of sclerodermatous cGVHD. J Cosmet Laser Ther 2020; 22: 49-51.
Nagler A, Pines M. Topical treatment of cutaneous chronic graft versus host disease with halofuginone: a novel inhibitor of collagen type I synthesis. Transplantation 1999; 68: 1806-1809.
Picardi A, Lanti A, Cudillo L et al. Platelet gel for treatment of mucocutaneous lesions related to graft-versus-host disease after allogeneic hematopoietic stem cell transplant. Transfusion 2010; 50: 501-506.
Wallace G, Myers KC, Teusink-Cross A, Davies SM, Khandelwal P, Jodele S. Topical vitamin D analog for chronic graft versus host disease of the skin. Bone Marrow Transplant 2018; 53: 628-633.
Weisdorf D, Haake R, Blazar B et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990; 75: 1024-1030.
Pidala J, Kurland B, Chai X et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the chronic GVHD consortium. Blood 2011; 117: 4651-4657.
Jacobs JM, Fishman S, Sommer R et al. Coping and modifiable psychosocial factors are associated with mood and quality of life in patients with chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2019; 25: 2234-2242.
Hymes SR, Turner ML, Champlin RE, Couriel DR. Cutaneous manifestations of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2006; 12: 1101-1113.
Rünger TM, Kappes UP. Mechanisms of mutation formation with long-wave ultraviolet light (UVA). Photodermatol Photoimmunol Photomed 2008; 24: 2-10.
Lee E, Koo J, Berger T. UVB phototherapy and skin cancer risk: a review of the literature. Int J Dermatol 2005; 44: 355-360.
Altman JS, Adler SS. Development of multiple cutaneous squamous cell carcinomas during PUVA treatment for chronic graft-versus-host disease. J Am Acad Dermatol 1994; 31: 505-507.
Stern RS, Lunder EJ. Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA): a meta-analysis. Arch Dermatol 1998; 134: 1582-1585.
Hamawy MM. Molecular actions of calcineurin inhibitors. Drug News Perspect 2003; 16: 277-282.
Safarini O, Keshavamurthy C, Patel P. Calcineurin Inhibitors. In StatPearl [Internet]. StatPearls Publishing, Treasure Island (FL), 2022.
Guenther L, Lynde C, Poulin Y. Off-label use of topical calcineurin inhibitors in dermatologic disorders. J Cutan Med Surg 2019; 23: 27S-34S.
Tennis P, Gelfand JM, Rothman KJ. Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors. Br J Dermatol 2011; 165: 465-473.
Couriel D, Carpenter PA, Cutler C et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: V. ancillary therapy and supportive care working group report. Biol Blood Marrow Transplant 2006; 12: 375-396.
Prignano F, Campolmi P, Bonan P et al. Fractional CO2 laser: a novel therapeutic device upon photobiomodulation of tissue remodeling and cytokine pathway of tissue repair. Dermatol Ther 2009; 22: S8-S15.
Pines M, Nagler A. Halofuginone: a novel antifibrotic therapy. Gen Pharmacol 1998; 30: 445-450.
Shattil S, Kashiwagi H, Pampori N. Integrin signaling: the platelet paradigm. Blood 1998; 91: 2645-2657.
Casale R, Buonocore M, Matucci-Cerinic M. Systemic sclerosis (Scleroderma): an integrated challenge in rehabilitation. Arch Phys Med Rehabil 1997; 78: 767-773.
Takahashi S, Hashimoto D, Hayase E et al. Ruxolitinib protects skin stem cells and maintains skin homeostasis in murine graft-versus-host disease. Blood 2018; 131: 2074-2085.
Kottner J, Surber C. Skin care in nursing: a critical discussion of nursing practice and research. Int J Nurs Stud 2016; 61: 20-8.
Szlauer-Stefańska A, Kamińska-Winciorek G, Giebel S, Bagłaj M. Secondary skin neoplasms in patients after autologous and allogeneic hematopoietic stem cell transplantation procedures. Adv Clin Exp Med 2020; 29: 1221-1230.
Carpenter PA, Kitko CL, Elad S et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: V. The 2014 ancillary therapy and supportive care working group report. Biol Blood Marrow Transplant 2015; 21: 1167-1187.
Szlauer-Stefańska A, Kamińska-Winciorek G, Giebel S. Onychoscopy of non-infectious nail abnormalities in patients after allogeneic haematopoietic stem cell transplantation. J Eur Acad Dermatol Venereol 2019; 33: 637-642.
Szlauer-Stefańska A, Kamińska-Winciorek G. What do the lips say in chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation? A case series. Dermatol Ther (Heidelb) 2021; 11: 1423-1434.